Study | Phase | Surgery | Dosing | Comparator(s) | Status |
---|---|---|---|---|---|
Dabigatran etexilate* | |||||
RE-NOVATE | III | THA | 150 and 220 mg od | Enoxaparin | Completed |
RE-MODEL | III | TKA | 150 and 220 mg od | Enoxaparin | Completed |
RE-MOBILIZE | III | TKA | 150 and 220 mg od | Enoxaparin‡ | Completed |
RE-NOVATE II | III | THA | 220 mg od | Enoxaparin | Completed |
Rivaroxaban† | |||||
RECORD1 | III | THA | 10 mg od | Enoxaparin | Completed |
RECORD2 | III | THA | 10 mg od | Enoxaparin | Completed |
RECORD3 | III | TKA | 10 mg od | Enoxaparin | Completed |
RECORD4 | III | TKA | 10 mg od | Enoxaparin‡ | Completed |
Apixaban | |||||
ADVANCE-1 (NCT00371683) | III | TKA | 2.5 mg bid | Enoxaparin‡ | Completed |
ADVANCE-2 (NCT00452530) | III | TKA | 2.5 mg bid | Enoxaparin | Completed |
ADVANCE-3 (NCT00423319) | III | THA | 2.5 mg bid | Enoxaparin | Completed |
YM150 | |||||
ONYX | II | THA | 3–60 mg od | Enoxaparin | Completed |
ONYX-2 | II | THA | 5–120 mg od | Enoxaparin | Completed |
PEARL-1 (NCT00408239) | II | TKA | Escalating doses (bid or od) | Enoxaparin | Completed |
PEARL-2 (NCT00595426) | II | TKA | bid or od | Warfarin | Completed |
ONYX-3 (NCT00902928) | II/III | THA | bid or od | Enoxaparin | Ongoing |
Edoxaban (DU-176b) | |||||
NCT00107900 | II | THA | Dose ranging | — | Completed |
NCT00398216 | II | THA | Dose ranging | Dalteparin | Completed |
Betrixaban | |||||
EXPERT | II | TKA | 15 or 40 mg od | Enoxaparin‡ | Completed |
bid = twice daily; od = once daily; THA = total hip arthroplasty; TKA = total knee arthroplasty; VTE = venous thromboembolism.
↵* Dabigatran etexilate was approved in the European Union and Canada for the prevention of VTE after THA and TKA in 2008.
↵† Rivaroxaban was approved in the European Union, Canada and several other countries for the prevention of VTE after THA and TKA in 2008.
↵‡ Enoxaparin 30 mg bid.
Source: www.clinicaltrials.gov.